Opasnosti vrebaju

Pacijent u ordinaciji ima pedesetak godina, izgleda mlađe. Oćelaveo od terapije, mada bih po konstituciji, odeći, i stavu—dva metra i mišićav, tri krsta i brojanica, vojnički i za dva decibila preglasan—pretpostavio da nikada nije imao bujne lokne.

Pričamo o ovom slučaju1.

- (Ja) mislim da seksualnih predatora, kidnapovanja, i zlostavljanja ima isto koliko i pre 20-30 godina, samo se sada mnogo više čuje o njima na TV-u pa roditelji misle da je rizik veći.

- Ma ne, kad sam ja bio mali nije ih bilo toliko. Sad ih je mnogo više, zbog Plejboja i ostalih gadosti.

- ?!

- O da, porno, strašna stvar, stvara perverznjake. Ne znam na šta će ta deca ličiti za 20 godina kad ih roditelji sad ne puštaju nigde. Prokleti Plejboj. Porno perverznjaci.

- OK… Alfa-fetoprotein i LDH su Vam normalni, izgleda da hemoterapija radi. Vidimo se za dva meseca, i uradite CT pre sledeće posete.

•••

Kukavica sam, priznajem.


  1. Skraćena verzija: Roditelji žele da sin i ćerka (10 i 6 godina) polako izgrade samostalnost. Šalju ih od kuće do prodavnice—put od kilometar i po koji prolazi kroz centar naselja i park. Prolaznik vidi dvoje dece bez pratnje i zove policiju (OK). Policija ih pita ko su i šta rade (OK). Klinci im objasne, ali nemaju papir koji inače nose sa sobom na kome je roditeljska dozvola. Policajci ih vraćaju nazad kući (OK), zatim zahtevaju pretres kuće, i zovu socijalne radnike (hmmm, ne…), koji od roditelja traže da potpišu da neće ostavljati decu same na ulici, uprkos tome što ne postoji ni jedan zakon koji to zabranjuje. Kada otac odbije, prete da će im uzeti decu (WTF). Nekoliko dana kasnije saznaju da su socijalni radnici išli u školu i tamo ispitivali decu o zlostavljanju u porodici (WTF⨉2). 

more ...


Clinical Center Grand Rounds — Moxetumomab for hairy cell leukemia

It was an honor to contribute to the NIH Clinical Center Grand Rounds this week—a straightforward presentation of a fascinating case, followed by the brilliant Drs. Kreitman and Pastan discussing the anti-CD22 immunotoxin Moxetumomab.

You can also view the talk on the NIH videocast page. Those fortunate few who have the time could spend days browsing through old lectures. Better use of resources that watching a TED talk, I’d say.

more ...

The more you know…

If the unstated goal of these rotation post-mortems was to summarize what I had learned, a single post may not be enough for breast cancer. Six weeks ago, I knew that it was common, maybe overdiagnosed, possibly overtreated, and beating all other cancers for research funding by a vast margin. All this was a vague sense of being informed—like a NYT reader may feel after reading the Sunday Magazine feature—rather than actual knowledge.

Having talked to a good number of women with breast cancer, and worked with a few attendings dedicated to the field, I know it enough to know that I need to know more; but also enough to keep me interested. What from the outside looks like cookbook this-marker-means-she’s-getting-that-treatment medicine is in fact an intricate work of knowing your patient, figuring out where she stands in the heaps of data generated by decades-long studies following thousands of women on different protocols, discussing the options, and coming to a mutualy agreed decision1. Hard work, all of it.

Harder still is working on those data-generating trials. Anyone can think of a clinicaly relevant question, but can they make it into a feasable protocol? Can they gather a team to manage all the patients in the center, and all the different centers? Can they manage that team? Looking at a recent set of trials you will hear more about soon, the scale boggles the mind.

Side note: “We don’t have a crystal ball” is common oncspeak for “I don’t know what your prognosis is”2, but if a person has breast cancer what are the Gail model or Oncotype DX if not (developing, imperfect) tellers of fortune? And wouldn’t it be great to have a similar set of tools and statistics for all cancers?

So, not going into the field, but thoroughly impressed.


  1. Which is—truth be told—what we should do for any cancer, or illness. Alas, most diseases lack data, options, or both. 

  2. Or in the paternalistic dialect of the language, “I don’t want to tell you that you prognosis is poor”.  

more ...

A tale of two interleukins

Another month, another slide show. This one is about two things I had no experience with prior to fellowship—interleukin 15, and chondrosarcoma.

The latter should be better known to surgeons, as most are resistant to all known types of chemotherapy or radiation. The only good way to get rid of them, then, is surgery. Which is fortunate, as they are usually very slow growing. Spoiler alert: our patient’s wasn’t.

Interleukin 15 should, in theory, have most of the benefits of interleukin 2 without the common side-effects of hypotension, hypoxia, and feeling like a steamroller ran over you. The not having adverse effects part has so far been true. Waiting to see what the outcomes are.

You can view a full-screen version of the slides here.

Error: Embedded data could not be displayed.

more ...

In the ivory tower

The rotation is called malignant hematology, but between Thanksgiving, Christmas, New Year’s, and everyone being away for ASH, it was a joke. The only memorable part were the first two weeks—the oncology consults at Georgetown—which reminded me that the NIH was indeed an ivory tower. This is compared to a well-known academic center. Compared to a community hospital—my last employer being a good example, though you may find much better—the Institutes in general and the Clinical Center in particular are a tower of crystalized angel tears sitting high on top of a mountain range on Mars. This is neither criticism nor praise, but a statement of fact2.

Having only spent four days on Georgetown consult service, I would rather not comment1. But here are ten things about the inpatient side of my home institution that might interest the outside world:

  • There is only one EMR and no paper charts;
  • Someone else, most commonly the research nurse, will obtain the outside records and have them scanned in—so the EMR is the only place you need to look for anything;
  • There are usually no medical students, interns, or residents—it’s the NP/PA, fellow, and the attending running the show;
  • Remember the 3am page from the nurse asking for a Tylenol order? If it is for someone on a phase 1 trial, you’d better check the protocol and call the attending before giving it;
  • Patients can be “out on pass”—meaning they can leave the campus for up to 20-something days and still count as an inpatient, without needing to be discharged and readmitted;
  • If a patient needs to stay an extra day or two because of transport issues, nobody blinks an eye;
  • For three to to five days you will get weird looks if it is your patient, but there will be no passive-aggresive emails about the hospital not getting reimbursement;
  • If it is six days or more it is likely they are homeless—social work will be on it;
  • Ordering most imaging—ultrasounds, CTs, MRIs, etc—requires two steps: getting a time-slot from central scheduling, or the tech on call if it is a same-day scan, and putting in the order. Think about the implications and let it sink in;
  • All discharge medications are dispensed from the outpatient pharmacy free of charge to the patient. Yes, all of them;

Most people treated at the Clinical Center are trial participants who are sick, rather than “just” patients. There are no administrative or financial pressures, no dealings with insurance companies, and not much concern with disposition. As you can imagine, this makes for a beautiful work environment.


  1. This makes it sound worse than it was. I don’t want to comment because n=4, not because I’m holding back the criticism. 

  2. Angel tears are a pain to clean up when they melt. 

more ...

Statistics resources for clinicians

Another week, another Quora question.

What is an online resource for learning statistics needed for clinicians explained in a language that could be understood by doctors?

There are many biostatistics courses available on Coursera. Living in Baltimore, I’m biased towards JHU’s offerings. “Case-Based Introduction to Biostatistics” by Dr. Scott Zeger is a good one. If you prefer text to video, here are three good resources:

If I had to pick one, it would be Dr. Brush’s book. He is a cardiologist writing for other physicians in a language they can understand. Also, Dr. Lehman recommended it, which is more than good enough for me.

more ...

BRAF mutations in non-small cell lung cancer

This was the last tumor board of the year, and the first in which I did not discuss a hematological malignancy.

Lung cancer is bad, doubly so when it’s metastatic, but looking at this patient’s history you can see it doesn’t necessarily mean months-not-years left. This particular patient is worthy of a case report, and one is indeed in progress.

As usual, I have removed all dates and images. There are quite a few post-thank you slides—enough for me to think about creating a dedicated lecture on chemotherapy for NSCLC.

Error: Embedded data could not be displayed.

You can view a full screen version of the slides here.

more ...

Why be a chief resident?

For the first time since joining Quora, I found a question to which I can meaningfuly contribute. Thought you might like to see my answer.

Why would someone choose to be a chief resident (in internal medicine)?

Why indeed.

The cynical answers would be “out of a misguided sense of loyalty to your program”. The correct and not very useful answer is—it depends.

Most positions entail primarily administrative responsibilities, with some teaching and clinical duties, and a salary just slightly higher than that of a PGY-3. So, you can expect your patient care skills to languish unless you work on maintaining them, your teaching skills to be slightly improved—or at least no worse if you’ve had some prior experience—and your knowledge of hospital administration, people management, dealing with email, and making the most out of seemingly pointless meetings to go through the roof. If you have any interest in academic medicine, as a generalist and sub-specialist alike, this last skill set will be invaluable. It is also a stamp of approval of sorts for any fellowship program director looking at your CV if and when you apply.

You also have much more free time. Depending on how many chiefs your program has, it will be most or all weekends, and almost all federal holidays. This is a good time to study for the boards if you haven’t taken them already, write up the research you’ve been working on, or spend some time with your family (the chief’s maternity/paternity leave is usually more flexible, but that’s program-dependent).

The downsides: you will have one fewer year of attending-level salary, so if you have a large debt or other financial responsibilities think twice before saying yes; some friendships you made with the junior residents will be undone or temporarily put on hold, unless you are very careful about not playing favorites; you may lose some respect for your higher-ups, as it goes whenever you peek behind the curtain; you will need to develop a thick skin, if you don’t have one already. Some would say these last two are actually pluses. It depends.

Visa issues complicate the matter, but I won’t go into details—bureaucracy shouldn’t play a role in determining a career choice, and when there is will (your own as well as the program’s) there is a way to bypass any obstacles.

Hope this helps.

more ...

A few good pens

Helping out Georgetown University fellows with their oncology consult service for a few days reminded me of how important it was to have at least three good pens with you at all times. By that, I don’t mean grabbing a handful of disposable Bics from a Staples shelf just because you know you will lose a lot—though you should certainly plan for theft and absent-mindedness. There are at least three different use cases you will face daily, and no pen will be ideal for all of them. I’ve tried out enough, and listened to plenty of podcasts on the topic, to be happy with my choices.

Role 1: The task keeper

Intern or fellow, this will be your most-used pen—the one you pull out to quickly jot and check off to-dos, make note of pertinent lab values and vital signs, and write down other important bits of information. If you are anything like me or my colleagues, you will be doing this on the signout, or some other piece of paper packed with information you might need.

This is why your pen should be:

  • as thin as possible, since you’ll likely write on the margins, but
  • not too faint, so it wouldn’t blend in with the rest of the text,
  • quick to use, since you’ll have to pull it out during rounds, patient encounters, and other situations in which fiddling with the cap would lead to losing both time and the cap, and
  • affordable, since you will misplace one every couple of months.

For the first two, the Uni Jetstream wins hands-down. The tip is as smooth as a 0.5 mm can be. It doesn’t skip, spill, sploch, or splat. The price is right—just $2.99 on jetpens.com. It is the best-in-class for every thing save one.

Zebra Sarasa Push Clip is not too thin, but thin enough to be scratchy and slightly annoying. Even with that small flaw, I choose it before the Jetstream. Because of the clip. The wonderful, magical clip.

You see, after four years of rounding, the act of pulling out a pen becomes a reflex. You hear something important, you have a thought, you blink, and you have a pen in one hand and your Very Important Paper in the other. You write something down, you blink, and your hands are free again. You are one with the sign out, and the pen.

To do that, you must at all times know where those two things are. The Very Important Paper is hard to miss, but the pen needs to be not just in the same pocket, but in the same spot in your pocket at all times. For me, the whitecoat-less fellow, that’s the inside of my left front pants pocket. This requirement rules out any clipless pens—goodbye, disposable Bics—but the regular clips don’t fare too well either. Too tight a clip, and you spend too much time fiddling it into the spot you want. Too loose, and it’s easy to put in, and easy to lose.

Which is why the clip is magical. You open it wide on entrance, and clamp it shut once you have the pen where you want it. It won’t budge after hours of walking up and down the hospital stairs. And, unlike one of my Jetstreams, it will be very difficult to break.

Alas, it only comes in one color. This is enough for the mild-to-moderate inpatient workload of a fellow, but during internship I needed the typical gunner pen to stay organized. Zebra Sarasa 3 is the high-end guner pen—one color fewer, but with the Zebra clip. For me today, it is just too bulky, I default to black anyway, and I’d just get annoyed with it running out way before the other two. But for me four year ago, it would have been perfect.

Role 2: The note writer

My choice: Ohto Graphic Liner Needle Point Drawing Pen - 02, 0.5 mm black Runner-up: Pilot Petit1 Mini Fountain Pen - Fine Nib, any colour

As much as I appreciate the ammount of writing I can cram onto a sign out with a thin pen, using one to write in paper charts, or for making notes on an old H&P while seeing a patient, creates an unreadable mess. The faint black lines of your pen blend in with the small type and the gray ruled lines of the progress note. Also, you don’t need as quick an access—a morning note-writing session may seem hectic, but you are the one who initiates the process. A couple of seconds looking for the pen or opening the cap won’t make you lose any information.

The Ohto liner leaves a consistent, dark line, lasts for ages, and is the right size for me. The ink is water-proof and archival safe—which is what you want for a medico-legal document. There’s a cap you need to worry about, but I’ve yet to lose one. And at $2.50 it won’t be the end of the world if I do.

This role can also be filled by a nice fountain pen—and you’ll see some attendings using one. I have had horrible luck finding a fountain pen that I won’t be afraid spilling in my bag or pocket, and most cost too much to carry around the hospital while sleep-deprived. The Pilot Petit1 pens have the right price, nice nib, and are easy enough to use. But I’m still too scared to put it in my pocket.

Role 3: The backup

My choice: Uni-ball Signo DX UM-151 Gel Ink Pen

This is the one you sprinkle around the house to be there just in case. The one you give out to friends and colleagues. And the one you use if you lose any of the others. If you needed to have just one pen, this would be the one, since it’s both thin and dark. Not perfect for either notes or task lists, but good enough.

At slightly less than $2 per pen it is afordable enough, though if you just want something to give out to others—and don’t care about them or their fingers—you can get a box of 60 horrible little stick for the price of three Signos. I guess you can give those out to your enemies and watch them writhe in pain and frustration.

Bonus: A pencil case

My choice: Kokuyo Will Stationery Actic Mini Pencil Case

This is entirely optional, but it saved me a surprising amount of time. It comfortably fits 4-5 pens and refills, and has good build quality. If your bag is small or you don’t mind fishing around for the pen you want, you can certainly do without it.

more ...